Skip to main content

Table 1 Demographic and clinical characteristic of COVID-19 patients

From: Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Characteristic Total (n=57) Severe (n=17) Non-severe (n=40) p Value
Age, year 46.72 (13.78) 52.53 (13.30) 44.25 (13.3) 0.031
Male gender, No 26 (45.6%) 12 (70.6%) 14 (35.0%) 0.014
BMI, kg/m2 23.99 (3.55) 25.54 (3.43) 23.33 (3.42) 0.103
Pre-existing medical illness 21 (36.8%) 7 (41.2%) 14 (35%) 0.658
LOS, days 20.89 (7.22) 20 (16-24) 19 (15-24) 0.834
WBC, ×10^9/L 5.01 (1.50) 4.47 (1.35) 5.24 (1.52) 0.076
lymphocyte count, ×10^9/L 1.60 (0.55) 1.30 (0.35) 1.72 (0.58) 0.008*
CRP, mg/dL 9.69 (13.77) 22.65 (18.19) 4.18 (5.66) <0.001*
LDH, U/L 175.47 (43.60) 201.94 (43.96) 164.22 (38.76) 0.002*
CK, U/L 91.95 (118.16) 133.18 (209.4) 74.42 (31.69) 0.235
Lactic acid, mmol/L 1.59 (0.61) 1.51 (0.65) 1.62 (0.59) 0.511
PaO2 to FiO2 ratio, mmHg 308.67 (94.40) 198.47 (97.04) 355.51 (37.23) <0.001*
TSS on the worst chest CT scan 4.28 (4.26) 8.59 (4.15) 2.45 (2.73) <0.001*
TSS on chest CT on the 14th day after discharge 1.75 (2.23) 3.94 (2.33) 0.83 (1.39) <0.001*
glucocorticoids use 16 (28.1%) 11 (64.7%) 5 (12.5%) <0.001*
Total methyprednisolone dosage, mg 213.75 (323.87) 289.09 (370.4) 48.0 (17.89) 0.019*
  1. Values are expressed as mean (SD)
  2. *Statistically significant